IgA Nephropathy Clinical Trial
Official title:
Treatment of IgA Nephropathy According to Renal Lesions
TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly randomized controlled study. The main objective is to evaluate the efficacy of early corticotherapy + Renin Angiotensin System (RAS) blockade or inhibitors of Sodium glucose transporter 2 (SGLT2i) (versus RAS blockade or SGLT2i alone) after two years of evolution in IgAN patients with severe histological lesions.
Currently, IgAN treatment recommendations are only based on clinico-biological parameters. Steroids therapy appears to have a major role in IgAN treatment, but previous studies evaluating steroids lacked of optimal control group and reproducible evaluation criteria. No prospective study with optimal nephroprotection had included renal pathology in patients selection criteria, although histological evaluation improves patients prognosis prediction. Until now, the lack of a reliable histological classification has precluded the use of histological lesions to evaluate IgAN prognosis and treatment. Given the recently identified major prognostic role of histological lesions in IgAN, we propose to introduce renal pathology to guide the treatment of IgAN in a multicenter study, using currently validated evaluation criteria of chronic kidney disease progression. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
| Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
| Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
| Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
| Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
| Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
| Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
| Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
| Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
| Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
| Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
| Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
| Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
| Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
| Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
| Recruiting |
NCT03001947 -
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
|
||
| Completed |
NCT01224028 -
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
|
Phase 2 |